Home/Filings/4/0001493152-21-025638
4//SEC Filing

Hagel Jillian Marie 4

Accession 0001493152-21-025638

CIK 0000890821other

Filed

Oct 17, 8:00 PM ET

Accepted

Oct 18, 8:03 AM ET

Size

18.5 KB

Accession

0001493152-21-025638

Insider Transaction Report

Form 4
Period: 2021-09-16
Hagel Jillian Marie
Chief Technology Officer
Transactions
  • Award

    Common Warrants

    2021-09-16+531,602531,602 total(indirect: See footnote)
    Exercise: $0.94From: 2021-09-16Exp: 2025-05-26Common Stock (531,602 underlying)
  • Award

    Common Warrants

    2021-09-16+1,3291,329 total
    Exercise: $2.82From: 2021-09-16Exp: 2023-09-16Common Stock (1,329 underlying)
  • Award

    Common Stock

    2021-09-16+82,39882,398 total
  • Award

    Common Stock

    2021-09-16+531,602531,602 total(indirect: See footnote)
  • Award

    Common Warrants

    2021-09-16+79,74079,740 total
    Exercise: $0.94From: 2021-09-16Exp: 2025-05-26Common Stock (79,740 underlying)
  • Award

    Stock Options

    2021-09-16+99,67599,675 total
    Exercise: $1.88From: 2021-09-16Exp: 2026-04-05Common Stock (99,675 underlying)
Footnotes (10)
  • [F1]Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the "Amalgamation Agreement"), by and among Enveric Biosciences, Inc. (the "Company"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), ("HoldCo"), 1306436 B.C. Ltd., ("Purchaser"), and MagicMed Industries Inc. ("MagicMed"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.2658 (the "Exchange Ratio") multiplied by the number of MagicMed shares held by each such MagicMed shareholder.
  • [F10]The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 5,000 shares of common stock of MagicMed with an exercise price of $0.75 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.
  • [F2]Received in exchange for 310,000 shares of common stock of MagicMed pursuant to the Amalgamation Agreement.
  • [F3]Received in exchange for 2,000,000 shares of common stock of MagicMed pursuant to the Amalgamation Agreement.
  • [F4]Held indirectly through the Hagel 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Hagel and her family.
  • [F5]Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each outstanding MagicMed stock option was converted into an option to purchase the number of Company shares equal to the Exchange Ratio multiplied by the number of MagicMed shares subject to such MagicMed stock option.
  • [F6]Received in exchange for options to acquire 375,000 shares of common stock of MagicMed with an exercise price of $0.50 per share in connection with the Amalgamation.
  • [F7]Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.
  • [F8]The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 300,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.
  • [F9]The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 2,000,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.

Documents

1 file

Issuer

Enveric Biosciences, Inc.

CIK 0000890821

Entity typeother

Related Parties

1
  • filerCIK 0001883891

Filing Metadata

Form type
4
Filed
Oct 17, 8:00 PM ET
Accepted
Oct 18, 8:03 AM ET
Size
18.5 KB